Edition:
India

Sienna Biopharmaceuticals Inc (SNNA.OQ)

SNNA.OQ on NASDAQ Stock Exchange Global Select Market

20.04USD
20 Apr 2018
Change (% chg)

$-0.46 (-2.24%)
Prev Close
$20.50
Open
$20.46
Day's High
$20.91
Day's Low
$19.81
Volume
30,374
Avg. Vol
39,696
52-wk High
$28.95
52-wk Low
$13.37

Latest Key Developments (Source: Significant Developments)

Sienna Biopharmaceuticals Announces First Patient Dosed In Proof-Of-Concept Trial Of Topical By Design JAK Inhibitor SNA-125 For Atopic Dermatitis
Monday, 12 Mar 2018 

March 12 (Reuters) - Sienna Biopharmaceuticals Inc ::SIENNA BIOPHARMACEUTICALS ANNOUNCES FIRST PATIENT DOSED IN PROOF-OF-CONCEPT TRIAL OF TOPICAL BY DESIGN™ JAK INHIBITOR SNA-125 FOR ATOPIC DERMATITIS.SIENNA BIOPHARMACEUTICALS INC - ‍TOP-LINE RESULTS FROM STUDY EXPECTED IN Q4 OF 2018​.SIENNA BIOPHARMACEUTICALS INC - ‍TRIAL TO ENROLL ABOUT 30 PATIENTS WITH ATOPIC DERMATITIS​.  Full Article

Sienna Biopharmaceuticals posts qtrly loss per share $1.12‍​
Thursday, 9 Nov 2017 

Nov 9 (Reuters) - Sienna Biopharmaceuticals Inc :Sienna Biopharmaceuticals reports third quarter 2017 financial results.Sienna Biopharmaceuticals Inc - Qtrly loss per share $1.12‍​.Sienna Biopharmaceuticals Inc - ‍Sienna's cash and cash equivalents as of Sept. 30, 2017, totaled approximately $88.6 million​.Sienna Biopharmaceuticals - ‍ Expects non-cash component related to acquisition of creabilis to continue to impact G&A expenses in future quarters​.  Full Article

Sienna Biopharmaceuticals announces first patient dosed in phase 2B trial of topical SNA-120
Tuesday, 24 Oct 2017 

Oct 24 (Reuters) - Sienna Biopharmaceuticals Inc :Sienna Biopharmaceuticals announces first patient dosed in phase 2B trial of topical SNA-120.Sienna Biopharmaceuticals Inc - ‍top-line results expected in first half of 2019​.Sienna Biopharmaceuticals - ‍phase 2B trial of topical SNA-120 to enroll about 190 patients with Pruritus associated with psoriasis​.  Full Article

Sienna Biopharmaceuticals announces pricing of initial public offering of common stock
Thursday, 27 Jul 2017 

July 26 (Reuters) - Sienna Biopharmaceuticals Inc :Sienna Biopharmaceuticals, Inc. announces pricing of initial public offering of common stock.Says initial public offering of 4.4 million shares of common stock at a public offering price of $15.00 per share.  Full Article

BRIEF-Sienna Biopharmaceuticals Appoints John Smither As CFO

* SIENNA BIOPHARMACEUTICALS APPOINTS JOHN W. SMITHER AS CHIEF FINANCIAL OFFICER